Main Menu

NIAID TTIPO’s extraordinary efforts in “COVID-19 Technologies Licensed Globally Through WHO Program” was recognized by the Licensing Executives Society (U.S.A. & Canada) in 2022 with a Deals of Distinction Award in the Industry-University-Government Interface Sector. This award acknowledged the collaborative efforts put forth by the WHO, Medicines Patent Pool (MPP) and the NIH for COVID-19 technologies licensed globally through the WHO program.

The United States Patent and Trademark Office (USPTO) recognized NIAID TTIPO’s public health-centered patent management efforts with the Patents for Humanity: COVID-19 category award with the USPTO announcing the award on December 15, 2022. NIAID, Scripps Research Institute, and Dartmouth College invented stabilized coronavirus spike proteins, which were essential to the development of the COVID-19 vaccines used today. The vaccines that incorporate these stabilized spike proteins have been instrumental in combating the COVID-19 pandemic.

In response to the COVID-19 outbreak, researchers and technology transfer professionals at NIAID accelerated collaborations with COVID-19 vaccine developers that enabled the rapid study, emergency authorization and public use of urgently needed vaccines. 

Through a CRADA with EMD Serono, NCI played an instrumental role in developing and 
expediting regulatory approval of EMD Serono’s checkpoint inhibitor, avelumab. Avelumab 
received FDA approval in 2017, only four years after EMD Serono and NCI added the study of 
avelumab to their CRADA. This was a remarkably fast developmental and regulatory approval 
timeline.

Rotavirus is a disease that affects nearly every child worldwide. While most cases have mild symptoms, it is responsible for one third of infant hospitalizations for severe diarrhea and kills an estimated 200,000 children a year, mostly in developing countries. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) developed vaccine formulations to address the six most common forms of rotavirus.

Rotavirus is a disease that affects nearly every child worldwide. While most cases have mild symptoms, it is responsible for one third of infant hospitalizations for severe diarrhea and kills an estimated 200,000 children a year, mostly in developing countries. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) developed vaccine formulations to address the six most common forms of rotavirus.

CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by healthcare workers. Exposure from contaminated surfaces and drug vials can cause skin problems, birth defects, reproductive issues, and increased risk of various cancers.

CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by healthcare workers. Exposure from contaminated surfaces and drug vials can cause skin problems, birth defects, reproductive issues, and increased risk of various cancers.

The National Institute for Allergy and Infectious Diseases (NIAID) has been recognized by the FLC for their impact on the public through their technology transfer work. On February 21, 2020 NIAID’s Division of Microbiology and Infectious Diseases (DMID) started an Adaptive COVID-19 Treatment Trial (ACTT) to test Gilead’s antiviral drug remdesivir, in a phase 3 trial. Remdesivir is an inhibitor of the viral RNA polymerase, so it became an early therapeutic candidate for COVID-19. This was the first clinical trial in the U.S. for an experimental treatment for COVID-19.

The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.